MECHANISM OF ACTION
Afatinib is an aniline-quinazoline derivative that is a highly selective, potent, and irreversible inhibitor of both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER2) kinases. 1 It covalently binds to EGFR, HER2, HER3, and HER4 and irreversibly blocks signaling from the molecules. 2, 3 Afatinib is active against an array of EGFR mutations that have been shown to be resistant to fi rst-generation EGFR tyrosine kinase inhibitors. 1, 4, 5 
PHARMACOKINETICS
Following oral administration of afatinib 40 mg every 24 hours, steady state is reached at 7 days. 1, 6 The median time to peak plasma concentration (T max ) is 5.49 hours after the fi rst dose 1 and 2.5 to 2.95 hours at steady state. 1, 6 The geometric mean area under the plasma concentration-time curve (AUC) at steady state is 968 ng•h/mL. 1 The mean maximum plasma concentration (C max ) is 21.1 ng/mL after the fi rst dose 1 and 29 ng/mL to 63.4 ng/mL at steady state. 1, 6 Administration of afatinib with a high-fat meal causes a 51% decrease in C max , a 37% decrease in AUC, and a 3.88 hour increase in T max compared to fasting administration. 1 Afatinib is 65% to 77% protein bound, 2 with an apparent volume of distribution (V d ) of 2,220 to 3,150 L at steady state. 1 Eighty-nine percent of a dose is eliminated as the parent compound. 2 The mean terminal half life (t ½ ) is 34 to 37.2 hours; the apparent clearance (CL) is 689 to 1,340 L/ min. 1, 6 Eighty-fi ve percent of afatinib is eliminated in the feces, and 4% is eliminated in the urine. 2 Selected therapeutic regimens of afatinib appear in Table 1 . Volume 49, March 2014
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http://evs. nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percentage unless incidence was less than or equal to 0.5%. A. Cardiovascular: Epistaxis (grade 1 or 2) 13%, 7 (grade 1) 16% to 30%. 3,6 B. Constitutional: Fatigue (grade 1 or 2) 16%, 7 (grade 3 or 4) 1%, 7 (grade 1) 17% to 21%, 3,6 (grade 2) 5% to 7%, 3,6 (grade 3) 3% to 5%. 3,6 C. Dermatologic: Cheilitis (grade 1 or 2) 12% 7 ; dermatitis acneiform (grade 1) 8% to 32%, 1,6 (grade 2) 16% 6 ; dry skin/xerosis (grade 1 or 2) 29%, 7 (grade 1) 3% to 20%, 1,3,6 (grade 2) 3% to 7%, 3 (grade 3 or 4) 0.4% 7 ; lip effects (grade 1) 7% 3 ; paronychia/nail effects (grade 1 or 2) 45%, 7 (grade 3 or 4) 11%, 7 (grade 1) 27%, 3 (grade 2) 47%, 3 (grade 3) 7% 3 ; pruritis (grade 1 or 2) 18%, 7 (grade 1) 37%, 3 (grade 2) 10%, 3 (grade 3 or 4) 0.4% 7 ; rash (grade 1) 32%, 6 (grade 2) 5% 6 ; erythematous rash (grade 1) 11% to 38%, 1,6 (grade 2) 31%, 1 (grade 3) 4% 1 ; rash or acne (grade 1 or 2) 73%, 7 (grade 1) 43%, 3 (grade 2) 40%, 3 (grade 3) 7%, 3 (grade 3 or 4) 16%. 7 D. Endocrine/Metabolic: Weight loss (grade 1) 7%, 3 (grade 2) 3%. 3 E. Gastrointestinal: Constipation (grade 1 or 2) 3% 7 ;
decreased appetite (grade 1 or 2) 17%, 7 (grade 1) 13% to 21%, 3,6 (grade 2) 5% to 13%, 3,6 (grade 3) 3% to 5%, 3,6 (grade 3 or 4) 3% 7 ; diarrhea (grade 1 or 2) 81%, 7 (grade 1) 42% to 63%, 1,3,6 (grade 2) 16% to 27%, 1,3,6 (grade 3) 7% to 11%, 1,3,6 (grade 3 or 4) 14% 7 ; nausea (grade 1 or 2) 17%, 7 (grade 1) 13% to 21%, 1,3,6 (grade 2) 3% to 5%, 6 
Name: Obinutuzumab
Synonyms: Gazyva, GA101
MECHANISM OF ACTION
Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody that has antibodydependent cellular cytotoxicity (ADCC) and induces direct cell death. 9 Glycoengineering, or modifi cation of specifi c sugar molecules in an antibody, generates new antibody variants with enhanced ability to recruit immune cells. The Fc region of the obinutuzumab antibody has been glycoengineered to reduce fucosylation (ie, addition of fucose sugar to molecule), which increases its affi nity for the FcγRIIIa receptor and enhanced ADCC potency. 10
PHARMACOKINETICS
Following a single intravenous (IV) infusion of a 800 mg dose, the mean AUC was 1,470 μg•h/mL, mean C max was 358 μg/mL, mean t ½ was 6.11 days, and mean CL was 347 mL/day. 11 Following a 1,200 mg dose, the mean AUC was 1,970 μg•h/mL, mean C max was 415 μg/mL, mean t ½ was 14.5 days, and mean CL was 248 mL/day. 11 Following 800 mg on day 1 and 1,200 mg on day 8, the mean AUC was 6540 μg•h/mL, mean C max was 669 μg/mL, mean t ½ was 14.2 days, and mean CL was 108 mL/day. 11 Following 800 mg on day 1, 1,200 mg on day 8, and 1,200 mg every 3 weeks for 7 cycles, the mean AUC was 10,800 μg•h/mL, mean C max was 1,040 μg/mL, mean t ½ was 27.2 days, and mean CL was 44.1 mL/ day. 11 The steady state V d of obinutuzumab is 3.8 L, the CL is 90 mL/day, and the t ½ is 28.4 days. 12 Elimination of obinutuzumab is probably by target mediated drug disposition, which results in faster than linear elimination. 12 Selected therapeutic regimens of obinutuzumab appear in Table 2 
